Hospitalization resource utilization and costs among medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 30-35

  Bera, Rimal ^a   Offord, Steve ^b   Zubek, Donna ^b   Lau, Gina ^b   Lin, Jay ^c   Karson, Craig ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c Novosys Health   (United States)

^d CNK Consultants   (United States)

Author keywords

Health care; Long acting injectable antipsychotics; Resource utilization; Schizophrenia; Treatment duration

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIPYRETIC AGENT; ANXIOLYTIC AGENT; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; RISPERIDONE; SEDATIVE AGENT; TRANQUILIZER;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MIDDLE AGED; OUTCOME ASSESSMENT; PREFERRED PROVIDER ORGANIZATION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT DURATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; COST SAVINGS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HEALTH RESOURCES; HOSPITAL COSTS; HUMANS; INJECTIONS; LENGTH OF STAY; LINEAR MODELS; MALE; MEDICAID; MIDDLE AGED; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; PATIENT ADMISSION; PATIENT READMISSION; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84891748522     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a6082a     Document Type: Article

References (21)

1. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:1-22.
2. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141:0413-33.
3. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122-1129.
4. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
5. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 2011;10:1-7.
6. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ. 2009;12(4):317-324.
7. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116(1):36-46.
8. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011;3:9-14.
9. Taylor M, Currie A, Lloyd K, et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol. 2008;22(2):128-131.
10. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006;114(1):14-20.
11. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 2009;120(2):97-101.
12. Noordsy DL, Phillips GA, Ball DE, et al. Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence. 2010;4:263-271.
13. Brissos S, Dias VV, Balanza-Martinez V, et al. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129 (2-3):133-136.
14. Cuyun Carter GB, Milton DR, Ascher-Svanum H, et al. Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry. 2011;11:1-12.
15. US Department of Health and Human Services. Code of Federal Regulations. Human Subjects Research (45 CFR 46). 2009. Available at: http://www.hhs.gov/ ohrp/humansubjects/guidance/45cfr46.html. Accessed January 22, 2013.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
17. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:1-10.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
19. Brown, JD, Barrett A, Ireys H, et al. Evidence-based practices for Medicaid Beneficiaries with schizophrenia and bipolar disorder. April 9, 2012. US Department of Health and Human Services. Available at: http://aspe.hhs.gov/ daltcp/reports/2012/ebpsbd.shtml. Accessed August 8, 2012.
20. Sommers BD. Loss of health insurance among non-elderly adults in Medicaid. J Gen Inter Med. 2009;24(1):1-7.
21. McFarland BH, Collins JC. Medicaid cutbacks and state psychiatric hospitalization of patients with schizophrenia. Psychiatr Serv. 2011;62(8):871-877.